International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationPrimary Analysis of a Phase II Randomized Trial Radiation Therapy Oncology Group (RTOG) 0212: Impact of Different Total Doses and Schedules of Prophylactic Cranial Irradiation on Chronic Neurotoxicity and Quality of Life for Patients With Limited-Disease Small-Cell Lung Cancer
Introduction
Small-cell lung cancer (SCLC) comprises approximately 13% of all cases of lung cancer being diagnosed more recently in the United States, of which roughly 30% are found to have limited disease (1). Despite the impact of chemotherapy and chest irradiation for treating the primary disease, brain relapses are still a major concern and may occur in approximately 50% of the time in long-term survivors (2). Although a meta-analysis (3) demonstrated the impact of prophylactic cranial irradiation (PCI) on improving survival in patients with limited-disease SCLC (LD SCLC) who sustained a complete response to chemoradiation, the optimal total dose and fractionation schedule of delivering PCI still remain uncertain.
Recently, the results of an international Phase III trial (PCI 01-EULINT1; ClinicalTrials.gov identifier: NCT 00005062) of more than 700 patients comparing 25 Gy in 10 daily fractions vs. 36 Gy total dose of PCI delivered at institutional choice in either 18 daily fractions or in 24 twice-daily delivered fractions showed no survival benefit in the higher-dose group (4). In fact, this latter study found a lower 2-year overall survival of 37% in the cohort receiving 36 Gy vs. 42% for those receiving 25 Gy (p = 0.05). This multinational PCI trial was already accruing patients at the time of concept development for Radiation Therapy Oncology Group (RTOG) trial 0212.
Therefore, with the support of the National Cancer Institute, RTOG 0212 was designed with two specific goals. First, the study was to contribute patients to the international PCI Phase III trial that evaluated the impact of total dose of PCI on the incidence of brain metastasis at 2 years, overall survival, and disease-free survival. The accrual to the international study was achieved in December 2005; 146 patients were enrolled from RTOG 0212 (4). Second, because there was a two-part randomization scheme not only between 25 Gy vs. 36 Gy total PCI dose but also between daily and twice-daily fractionation with the 36-Gy total PCI dose arms, RTOG 0212 was planned as a Phase II trial to determine the impact of PCI total dose and treatment schedule on incidence of chronic neurotoxicity (CNt) and on quality of life (QoL). This study required a total of 264 evaluable patients, including the first 146 patients coenrolled into the international study, to perform its objectives. Thus, this report is an analysis of the initial results of RTOG 0212.
Section snippets
Patient selection
Histologic or cytologic evidence of SCLC was required. After appropriate staging workup and Zubrod performance status of ≤1 along with RTOG neurological function class of 1 or 2, patients had to have limited disease and achieved a complete response to chemotherapy and consolidative chest radiotherapy that was documented at least on standard chest X-rays within 1 month of study entry. Patients may still have been receiving chest irradiation but must have completed chest irradiation by at least 1
Results
Radiation Therapy Oncology Group Protocol 0212 opened on February 19, 2003 and closed on February 12, 2008. A total of 265 patients were accrued, of whom 264 were eligible for analysis. This evaluation was performed using those eligible patients in RTOG 0212 as of February 23, 2009.
At the time of this analysis, there are 112 patients alive with 25.3 months of median follow-up (range, 0–53.0 months), with 16 patients having less than 12 months of follow-up. There was 1 patient in Arm 2 for whom
Discussion
Since the sentinel meta-analysis published in 1999 regarding 987 patients from seven randomized trials (3), the standard of care for patients with LD SCLC who achieve a complete response after chemoradiation for the primary disease has been to incorporate PCI into their therapeutic regimen. In addition to reducing the risk of brain metastases from 58.6% without PCI to 33.3% at 3 years, PCI was found to result in a 16% reduction in mortality rate that translated into a 5.4% increase in 3-year
References (45)
- et al.
Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): A randomized clinical trial
Lancet Oncol
(2009) - et al.
Prophylactic cranial irradiation: More questions than answers
Semin Radiat Oncol
(1995) - et al.
Cerebral toxicity in patients treated for small cell carcinoma of the lung
Mayo Clin Proc
(1999) - et al.
Changes in early and late radiation responses with altered dose fractionation: Implications for dose-survival relationships
Int J Radiat Oncol Biol Phys
(1982) - et al.
Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentre randomised trial
Eur J Cancer
(1997) - et al.
Follow-up of cognitive functioning in patients with small cell lung cancer
Int J Radiat Oncol Biol Phys
(1995) - et al.
Sequelae in long-term survivors of small cell lung cancer
Int J Radiat Oncol Biol Phys
(1996) - et al.
Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation
Int J Radiat Oncol Biol Phys
(1995) - et al.
Cognitive deficits in patients with small cell lung cancer before and after chemotherapy
Lung Cancer
(1995) - et al.
Cancer statistics, 2008
CA Cancer J Clin
(2008)
Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation
Cancer Treat Rep
Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission
N Engl J Med
Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability
Clin Neuropsychol
Multilingual aphasia examination
Neuropsychological assessment
Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group
Qual Life Res
The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires
Qual Life Res
The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
J Natl Cancer Inst
Quality of life during chemotherapy for small cell lung cancer. II. A longitudinal study of the EORTC Core Quality of Life Questionnaire and comparison with the Sickness Impact Profile
Acta Oncol
Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients
Acta Oncol
Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer
Qual Life Res
A validation study of the domains of the core EORTC quality of life questionnaire
Qual Life Res
Cited by (233)
Risk factors for cognitive impairment in radically treated stage III NSCLC: Secondary findings of the NVALT-11 study
2023, Radiotherapy and Oncology
Supported by Grants RTOG U10 CA21661, CCOP U10 CA37422, and Stat U10 CA32115 from the National Cancer Institute. ClinicalTrials.gov identifier: NCT00057746. This article's contents are the sole responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
Conflict of interest: none.